Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/UMEC/VI vs FF/VI in 12-17-year-old Participants With Inadequately Controlled Asthma
NCT05757102Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of umeclidinium in asthma, sponsored by GSK. Started Apr 2023; status: active, not recruiting.
02
Drugs
umeclidinium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05757102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757102.